article thumbnail

Sorry, the Inflation Bill won’t lower healthcare costs

World of DTC Marketing

1ne: A new analysis predicts that by 2030, 48.9% Increased provider consolidation has decreased individual market competition, in which lower prices, improved productivity, and innovation can occur. Without this competition, these near-monopolies have providers and insurers in a position where they can drive up their prices unopposed.

article thumbnail

Pharmapack Europe 2025: Eco barrier packaging to launch

European Pharmaceutical Review

The new Eco Line product family demonstrates our commitment to delivering sustainable, eco-friendly barrier bottles at competitive prices,” added Bassi. As such, bottle weight is reduced by up to 30 percent without compromising on Water Vapor Transmission Rate (WVTR).

Pharma 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bayer sells testosterone drug rights to Grünenthal for €500m

pharmaphorum

The two companies said the transaction is expected to close by the end of 2022, subject to approval by the competition authorities.

article thumbnail

2022 Sales Hiring Forecast

Sales Talent

However, before you jump directly to our sales hiring predictions for 2022, take the time to read the entire article to learn how the intense competition for talent is impacting sales professionals’ salaries and employers’ strategies for winning the talent war. jobs by 2030 while the workforce will only grow by 8.9M.

Sales 130
article thumbnail

$2 billion mRNA-based oncology therapy market anticipated by 2029

European Pharmaceutical Review

billion by 2030 BioNTech Development of mRNA-based oncology therapies for German biotech BioNTech is progressing. Omega Therapeutics’s share suggests increasing competition and diversification in this innovative field,” concluded Podder. Global RNA therapy clinical trials market to reach $3.5 subvariant.

Marketing 110
article thumbnail

4D Molecular’s Fabry gene therapy program on FDA clinical hold

Pharmaceutical Technology

4DMT is creating a gene therapy using an adeno-associated viral vector (AAV) and there is currently competition from several early-stage therapies in trial, such as Sangamo Therapeutics’s Fabry gene therapy that is currently at Phase III, which also uses AAV, and as of November 2022 has reported it is progressing to late-stage plans.

FDA 105
article thumbnail

Vaccines Europe launches first pipeline review

European Pharmaceutical Review

The time to population access for vaccines exceeds six years in a third of States, and the procurement mechanism for vaccines in most States doesn’t facilitate fair competition, timely access to vaccines and sustainable supply. The pipeline review determined there are disparities in market access to vaccines across Europe.